Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Precision BioSciences, Inc. DTIL
$0.76
+$0.01 (1.75%)
На 18:01, 12 мая 2023
+31.58%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
84330480.00000000
-
week52high
2.21
-
week52low
0.68
-
Revenue
25098000
-
P/E TTM
-1
-
Beta
1.37231200
-
EPS
-1.22000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Neutral | Neutral | 09 авг 2022 г. |
| BMO Capital | Outperform | 17 июн 2022 г. | |
| William Blair | Market Perform | Outperform | 09 июн 2022 г. |
| Goldman Sachs | Neutral | Neutral | 16 мар 2022 г. |
| Stifel | Buy | Buy | 10 сент 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 10 ноя 2022 г. |
| Goldman Sachs | Neutral | Neutral | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Scimeca Dario | A | 178000 | 178000 | 20 янв 2023 г. |
| List Alan | A | 180000 | 180000 | 20 янв 2023 г. |
| Amoroso Michael | A | 800000 | 800000 | 20 янв 2023 г. |
| Barton Shane | A | 70000 | 70000 | 20 янв 2023 г. |
| Kelly John Alexander | A | 350000 | 350000 | 20 янв 2023 г. |
| SMITH J. JEFFERSON | A | 225000 | 225000 | 20 янв 2023 г. |
| Scimeca Dario | A | 165200 | 165200 | 02 ноя 2022 г. |
| Amoroso Michael | A | 850000 | 850000 | 02 ноя 2022 г. |
| Kelly John Alexander | A | 324500 | 324500 | 02 ноя 2022 г. |
| Amoroso Michael | A | 250000 | 250000 | 24 окт 2022 г. |
Новостная лента
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 09:57
Precision BioSciences (DTIL) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.46 per share a year ago.
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
09 мар 2023 г. в 09:53
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
Business Wire
22 февр 2023 г. в 07:00
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright Cell Therapy Virtual Conference taking place February 28, 2023.
There's a Lot of Upside For Emerging Gene-Editing Companies
MarketBeat
21 февр 2023 г. в 09:16
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter how good or bad they might be doing right now, there is likely much more to come.
Precision BioSciences: A Watch List Stock Going Into ASH Presentation
Seeking Alpha
06 дек 2022 г. в 04:34
Precision BioSciences has been on the candidate list for my Compounding Healthcare “Bio Boom” Portfolio. I am looking to find a spot for DTIL ahead of the ASH presentations. I intend to provide a brief background on Precision BioSciences and will discuss why I believe DTIL deserves a spot in the Bio Boom Portfolio.